Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26838901 | 0.84 | CA12 (0.35) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL24298555 | 0.84 | CA12 (0.35) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL19519894 | 0.81 | CTSK (0.33) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL3863085 | 0.81 | CA12 (0.35) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL21364508 | 0.79 | TOP1 (0.38) | CTSK | |
| SCHEMBL19519893 | 0.79 | ALDH1A1 (0.33) | TDP1CA2CA12CA14CTSK | |
| SCHEMBL29601090 | 0.78 | CA2 (0.33) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL24323964 | 0.78 | CA2 (0.33) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL5787433 | 0.77 | DGAT1 (0.38) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL5787436 | 0.77 | DGAT1 (0.38) | TDP1MEN1GAAKMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TDP1 4527/4885MEN1 4643/4885GAA 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.